The U.S. Food and Drug Administration (FDA) has approved ZEGERID OTC(TM) (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules), for over-the-counter treatment of frequent heartburn. ZEGERID OTC will be marketed over-the-counter by Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc. Schering-Plough and Merck merged on November 3, 2009.

ZEGERID OTC is a proton pump inhibitor (PPI), the strongest and most effective class of acid-reducing medications available for frequent heartburn. ZEGERID OTC treats frequent heartburn by controlling and suppressing acid for a full 24 hours, all day and all night.

ZEGERID OTC contains a patented dual-ingredient formulation that combines the leading prescription acid reducing medicine (omeprazole) with sodium bicarbonate, which protects the omeprazole from acid in the stomach. ZEGERID OTC capsules will be available in their original prescription formula, and are expected to be available at drug stores, grocery stores, mass merchandisers and club stores in the first half of 2010.

The approval provides a new and unique over-the-counter option for the estimated 50 million American adults who experience symptoms associated with frequent heartburn — defined by symptoms occurring more than 2 times per week — with up to 25 million Americans experiencing heartburn on a daily basis.

ZEGERID OTC(TM) is a 14-day course of treatment taken once per day to treat frequent heartburn as directed. For more information about ZEGERID OTC, visit www.ZegeridOTC.com.

ZEGERID OTC capsules add to the Schering-Plough HealthCare Products, Inc. expanding portfolio of gastrointestinal OTC products such as MiraLAX® laxative, which was launched in 2007 for the treatment of occasional constipation. ZEGERID OTC(TM) is the most recent example of the Schering-Plough HealthCare Products, Inc. legacy of successful switches of medications from prescription to over-the-counter status. This portfolio of products includes brands such as CLARITIN®, MiraLAX®, LOTRIMIN®, AFRIN®, CORICIDIN®, TINACTIN®, and DRIXORAL®. Many of these products are market-leading brands in their respective category.

Under an agreement with Santarus, a specialty pharmaceutical company that developed and currently markets prescription ZEGERID®, Schering-Plough HealthCare Products is responsible for the development, manufacturing and commercialization of ZEGERID OTC products for heartburn-related indications in the U.S. and Canada. Santarus will continue to manufacture, promote and sell its ZEGERID (omeprazole/sodium bicarbonate) products in both 20 mg and 40 mg dosage strengths in the U.S.

For additional information on prescription ZEGERID, please visit www.Zegerid.com.

Related Health News:

1. Repligen Licenses Patent Rights for Treatment of Bipolar Disorder WALTHAM, Mass., March 31 /PRNewswire-FirstCall/ — Repligen Corporation (NASDAQ:RGEN) announced today that it has exclusively licensed worldwide rights for the use of uridine in the...
2. Aethlon Medical Discloses New HIV AIDS Treatment Data SAN DIEGO, May 5 /PRNewswire-FirstCall/ — Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) today disclosed new data resulting from its recent “first-in-human” application of the...
3. Orthotics And Beyond Expands Plantar Fasciitis Night Splint Offerings to Give Personalized Treatment Options Orthotics And Beyond has dramatically expanded its plantar fasciitis and night splint solutions to offer new combination treatments and personalized therapies. Plantar fasciitis is characterized...
4. CVS Caremark Extends Google Health Partnership Customers can now securely download their prescription history from cvs.com to their Google Health Account WOONSOCKET, R.I., April 6 /PRNewswire/ — CVS Caremark today announced...
5. Mylan Announces Clarinex Settlement Agreement PITTSBURGH, April 8 /PRNewswire-FirstCall/ — Mylan Inc. (NASDAQ:MYL) today announced the settlement of all patent litigation relating to Desloratadine Tablets, 5 mg, the generic version...